Skip to main content

Table 3 Multivariable Cox model analyses

From: Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis

VariablesOSiPFS
HR95%CIpaHR95%CIpa
WBRT (Gy)
 none1.000 ref.1.000 ref.
  < 301.227(0.787–1.914)ns1.625(1.045–2.528)0.031
 30–390.722(0.500–1.042)0.0820.714(0.502–1.017)0.062
  ≥ 400.609(0.453–0.818)0.0010.669(0.500–0.895)0.007
Local/boost RT (Gy)
 none1.000 ref.1.000 ref.
  < 500.609(0.341–1.088)0.0420.930(0.555–1.561)ns
 50–590.572(0.402–0.815)0.0030.776(0.551–1.092)0.146
  ≥ 600.580(0.385–0.873)0.0190.641(0.427–0.963)0.032
SRT0.653(0.326–1.308)0.0220.708(0.364–1.376)ns
Female0.798(0.644–0.988)0.0390.8040.655–0.987)0.037
CVD0.868(0.706–1.068)0.1820.936(0.765–1.145)ns
Age (years)
  < 501.000 ref.1.000 ref.
 50–591.089(0.799–1.486)ns0.8540.638–1.142)ns
  ≥ 601.335(0.990–1.800)0.0581.0880.820–1.444)ns
KPS
  < 701.000 ref.1.000 ref.
 70–800.987(0.762–1.279)ns0.964(0.748–1.241)0.774
  ≥ 900.620(0.479–0.801)0.0000.670(0.521–0.862)0.002
NSCLC history (month)
  < 10.632(0.473–0.844)0.0020.780(0.595–1.023)0.072
 1–60.895(0.626–1.280)ns1.249(0.891–1.750)0.197
 6–120.741(0.525–1.045)0.0870.828(0.590–1.160)ns
  > 121.000 ref.1.000 ref.
BM lesion number
 11.000 ref.1.000 ref.
 2–31.181(0.870–1.602)ns1.023(0.766–1.366)ns
  ≥ 41.325(1.045–1.681)0.0201.148(0.911–1.447)ns
Extracranial met.1.313(1.019–1.691)0.0351.836(1.428–2.361)0.000
Brain stem met.1.219(0.664–2.235)ns1.009(0.548–1.857)ns
Meningeal met.0.935(0.633–1.382)ns1.136(0.772–1.670)ns
Targeted therapy0.373(0.290–0.480)0.0000.506(0.402–0.636)0.000
Chemotherapy0.587(0.476–.724)0.0000.724(0.592–0.885)0.002
BM resection
 none1.000 ref.1.000 ref.
 incomplete0.834(0.200–3.482)ns0.854(0.206–3.532)ns
 complete0.709(0.429–1.171)0.1800.9090.557–1.486)ns
Lung tumor surgery
 none1.000 ref.1.000 ref.
 incomplete0.889(0.533–1.482)ns0.911(0.559–1.483)ns
 radical0.773(0.553–1.080)0.1320.705(0.508–0.978)0.036
  1. OS overall survival; iPFS intracranial progression-free survival; HR hazard ratio; 95%CI 95% confidence interval; WBRT whole brain radiotherapy; ref. reference; ns not significant with p > 0.20; RT radiotherapy; SRT stereotactic radiotherapy; CVD cardiovascular disease; BM brain metastases; KPS Karnofsky Performance Score; NSCLC non-small cell lung cancer; met. Metastases.
  2. a from the multivariable Cox model analysis.